Table III.

Demographic, clinicopathological factors and leptin, adiponectin markers in association with hepatocellular carcinoma survival among those without liver transplant.

Variables	Survival status, No (%)		p-Value
	Alive	Dead
Age group
<62.6 years	23 (36.5)	40 (63.5)
≥62.6 years	25 (34.7)	47 (65.3)	0.829
Gender
Female	10 (33.3)	20 (66.7)
Male	38 (36.2)	67 (63.8)	0.773
Race/ethnicity
Non-Hispanic White	17 (27.0)	46 (73.0)
Others	31 (43.1)	41 (56.9)	0.052
Hepatitis B virus infection
Negative	35 (31.5)	76 (68.5)
Positive	13 (54.2)	11 (45.8)	0.036
Hepatitis C virus infection
Negative	20 (33.9)	39 (66.1)
Positive	28 (36.8)	48 (63.2)	0.411
Alcohol drinking history
No	33 (33.0)	67 (67.0)
Yes	15 (42.9)	20 (57.1)	0.294
Cigarette smoking
Never	19 (36.5)	33 (63.5)
Ever	27 (35.1)	50 (64.9)	0.864
Diabetes mellitus history
No	28 (38.9)	44 (61.1)
Yes	20 (31.8)	43 (68.3)	0.387
Body mass index at enrollment (kg/m2)
<30	18 (40.9)	26 (59.1)
≥30.0	25 (32.1)	53 (67.9)	0.325
Waist to hip ratio
<0.953	23 (38.3)	37 (61.7)
≥0.953	17 (28.8)	42 (71.2)	0.272
α-fetoprotein (ng/ml)
<48	26 (44.8)	32 (55.2)
≥48	22 (28.6)	55 (71.4)	0.051
Child-Pugh class
A	33 (40.2)	49 (59.8)
B	14 (26.9)	38 (73.1)	0.115
Metastasis
No	44 (41.1)	63 (58.9)
Yes	2 (10.5)	17 (89.5)	0.011
Milan criteria
Within	23. (59.0)	16 (41.0)
Outside	25 (26.0)	71 (74.0)	<0.001
Barcelona clinic liver cancer stage
0, A	23 (57.5)	17 (42.5)
B, C	25 (26.3)	70 (73.7)	0.001
Cancer antigen 19-9 (U/ml)
<38.0	24 (38.1)	39 (61.9)
≥38.0	23 (32.9)	47 (67.1)	0.528
Leptin (ng/ml)
<Median	26 (37.1)	44 (62.9)
≥Median	22 (33.9)	43 (66.1)	0.689
Adiponectin (μg/ml)
<Median	28 (41.2)	40 (58.8)
≥Median	20 (29.9)	47 (70.1)	0.169